Kathryn Stensgard
Family · Bismarck, NDNPI 1437591062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$807
- Novo Nordisk$762
- Amgen$659
- AbbVie$348
- Pfizer$326
- Novartis$253
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 64 | $807 |
| Novo Nordisk | 59 | $762 |
| Amgen | 45 | $659 |
| AbbVie | 23 | $348 |
| Pfizer | 24 | $326 |
| Novartis | 16 | $253 |
| Boehringer Ingelheim | 16 | $222 |
| AstraZeneca | 7 | $187 |
| Bayer | 9 | $145 |
| E.r. Squibb & Sons, L.L.C. | 7 | $113 |
| Abbott | 5 | $83 |
| Astellas Pharma US Inc | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Johnson & Johnson | 4 | $56 |
| Phathom Pharmaceuticals, Inc. | 4 | $52 |
| Madrigal Pharmaceuticals | 2 | $51 |
| GSK | 3 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Boston Scientific | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Dexcom, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Merck | 1 | $14 |
| Biogen | 1 | $13 |
How this compares
$4,699 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 65 | $68,672 |
| EliquisApixaban | 62 | $48,822 |
| OzempicSemaglutide | 24 | $42,329 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $27,953 |
| Bydureon BciseExenatide Microspheres | 16 | $19,688 |
| MounjaroTirzepatide | 15 | $14,817 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $14,657 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $10,882 |
| TrulicityDulaglutide | 12 | $10,726 |
| MyrbetriqMirabegron | 15 | $8,434 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,289 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,085 |
| Novolog FlexpenInsulin Aspart | 15 | $3,950 |
| Metoprolol Succinate | 137 | $3,903 |
| Levothyroxine Sodium | 237 | $3,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $222 | $68,67265 claims |
| PfizerEliquis, Abrysvo | $326 | $53,90779 claims |
| Novo NordiskOzempic | $762 | $42,32924 claims |
| Lilly USA, LLCMounjaro, Trulicity | $807 | $25,54227 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $47 | $22,84940 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $8,43415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.
Other family in Bismarck
- Courtney WoodburyBismarck$8K
- Monica GoetzBismarck$8K
- Elizabeth ScheurerBismarck$6K
- Kayla HolzerBismarck$5K
- Amanda AllmarasBismarck$5K
- Sally FrankBismarck$4K
- Amy GotvasleeBismarck$4K
- Michelle MaierBismarck$4K
- Tanya GuthmillerBismarck$4K
- Amanda HelmBismarck$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.